Stockwinners Market Radar for July 29, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:04 EDT Northrop Grumman awarded $3.29B government contract - Northrop Grumman Systems Corp., Huntsville, Alabama is being awarded an indefinite-delivery/indefinite-quantity contract with a maximum amount of $3,286,745,005. Under this new contract, the contractor will design, develop, test, and field the next Ground-Based Midcourse Defense Weapon System Program. The GWS contract covers the systems engineering, design, development, integration, testing, and fielding of GWS software and hardware meeting warfighter needs, new requirements and evolving threats with greater reliability, availability, maintainability and testability than the current system. Delivery Order 0001 in the amount of $716,090,100; Delivery Order 0002 in the amount of $423,546,873; and Task Order 0001 in the amount of $115,299,142 are being issued at this time. The work will be performed in Huntsville, Alabama. The ordering period is from July 29, 2022, through July 29, 2027. This contract was competitively procured via publication on the Government-wide Point of Entry website with one proposal received. Fiscal 2022 research, development, test and evaluation funds in the amount of $76,355,001; and fiscal 2022 operations and maintenance funds in the amount of $200,000 are being obligated on this award. The fiscal 2022 operations and maintenance funds will expire at the end of the current fiscal year. The Missile Defense Agency, Huntsville, Alabama, is the contracting activity.

17:01 EDT Horizon Global addresses NYSE continued listing standards - Horizon Global Corporation announced that on July 25, 2022, it received a letter from the New York Stock Exchange informing the company of its non-compliance with NYSE continued listing standards because the company's average market capitalization over a recent consecutive 30 trading-day period has been less than $50,000,000 and, at the same time, stockholders' equity was less than $50,000,000. The company has 45 business days to notify the NYSE of its intent to cure this deficiency and Horizon Global intends to do so on a timely basis. In accordance with NYSE procedures, the company intends to submit a plan to the NYSE demonstrating how it intends to regain compliance with the continued listing standards on or prior to January 25, 2024. The notice from the NYSE has no immediate impact on the listing of the Company's common stock, which will continue to trade on the NYSE under the symbol "HZN", but will be assigned a ".BC" indicator to signify that the Company is not currently in compliance with NYSE continued listing standards. The NYSE notification does not affect Horizon Global's business operations, its Securities and Exchange Commission reporting requirements, or any of the Company's material debt agreements.

16:35 EDT Independent Bank names Paul Langdale as CFO, replacing Michelle Hickox - Independent Bank Group announced the appointment of Paul Langdale as CFO. Langdale is replacing Michelle Hickox, who has served as CFO of Independent Bank Group and its subsidiary, Independent Bank since 2012. Hickox will remain employed in an advisory capacity to facilitate the transition until October 1. Langdale joined the company in 2018, and has held increasingly senior positions in finance, investor relations and corporate development, most recently serving as Executive Vice President, Corporate Development & Strategy.

16:32 EDT Tuesday Morning CFO Jennifer Robinson to depart, Marc Katz named interim CFO - Tuesday Morning announced that Jennifer Robinson, who has served as Executive Vice President and CFO since September 2021 is departing the company to pursue other opportunities effective August 15. Marc Katz, Principal and COO of Tuesday Morning, will serve as Interim CFO of the company.

16:16 EDT Oppenheimer Holdings announces 536,500 share repurchase program - Oppenheimer Holdings announced that its Board of Directors approved a share repurchase program that authorizes the company to purchase up to 536,500 shares of the company's Class A non-voting common stock, representing approximately 4.8% of its 11,251,930 currently issued and outstanding shares of Class A non-voting common stock. This authorization will supplement the 4,278 shares that remain authorized and available under the company's previous share repurchase program covering up to 550,000 shares of the company's Class A non-voting common stock, which was announced on May 24, for a total of 540,778 shares authorized and available for repurchase. The share repurchase program is expected to continue indefinitely.

16:00 EDT Alpha Capital Acquisition Company (Class A Stock) trading resumes

15:36 EDT Brookline Capital Acquisition Corporation trading resumes

15:31 EDT 1895 Bancorp of Wisconsin announces share repurchase plan - 1895 Bancorp of Wisconsin announced that it has adopted a stock repurchase program for up to 5% of its outstanding common stock. This is the company's first stock repurchase program since completing its second step reorganization and related stock offering in July 2021, and is subject to regulatory non-objection. The repurchase program has no expiration date.

14:55 EDT FDA provides update on agency response to monkeypox outbreak - The U.S. Food and Drug Administration is providing an update on its multipronged response to monkeypox in the United States, including its efforts in the areas of diagnostics, vaccines and therapeutics. "The FDA will provide updates as developments occur and will continue to work with federal public health partners and industry to ensure timely access to all available medical countermeasures," it stated. The FDA said: "Since the first case of monkeypox in the U.S. was detected, the FDA has been working with commercial laboratories and manufacturers to make monkeypox tests more readily available to consumers who need them. The Centers for Disease Control and Prevention has an FDA-cleared non-variola orthopoxvirus test that can detect monkeypox by a swab from a monkeypox lesion. At this time, this is the only FDA-cleared test... In 2019, the FDA approved the JYNNEOS Vaccine for the prevention of smallpox and monkeypox in adults 18 years of age and older determined to be at high risk of infection. JYNNEOS is the only vaccine approved for the prevention of monkeypox in the United States. Although clinical trials and data are limited because of the small number of cases until now, the immunological response to vaccine administration is consistent with effective prevention of the disease... There is no FDA-approved or authorized medicine for the treatment of monkeypox disease; however, TPOXX, an antiviral medication, is being made available through the CDC under an FDA authority called Expanded Access or 'compassionate use.' The FDA continues to work with the CDC to streamline their Expanded Access Program for monkeypox to facilitate access. There are currently no human data demonstrating the efficacy of TPOXX for the treatment of monkeypox, or the safety and pharmacokinetic profile. Although expanded access program is available, conducting randomized, controlled trials to assess TPOXX's safety and efficacy in humans with monkeypox infections is essential." On July 15, Bavarian Nordic (BVNRY) announced that the U.S. Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has ordered an additional 2.5 million doses of liquid-frozen JYNNEOS, a non-replicating smallpox vaccine and the only FDA-approved vaccine against monkeypox. SIGA Technologies (SIGA) is the maker of oral TPOXX. Reference Link

14:46 EDT Siga Technologies trading halted, volatility trading pause

14:12 EDT Zhong Yang Financial Group Ltd trading resumes

14:02 EDT Zhong Yang Financial Group Ltd trading halted, volatility trading pause

13:33 EDT Kaltura says will evaluate $3 per share takeover proposal from Panopto - Kaltura said it is aware of the public announcement made by Panopto, a private company owned by K1 Investment Management, regarding a "non-binding, unsolicited proposed business combination transaction" in which Panopto would acquire all of the company's outstanding common stock at a purchase price of $3.00 per share in cash. Kaltura said its board "will evaluate the proposal in due course." It added, "Kaltura continues to execute on its strategy to power video experiences for learning, collaboration, entertainment, and events for organizations around the world."

13:26 EDT Dr. Reddy's announces licensing pact with Slayback for private label Lumify - Dr. Reddy's Laboratories announced that it has entered into a licensing agreement with Princeton, New Jersey based Slayback Pharma to acquire rights in Slayback's Brimonidine Tartrate Ophthalmic Solution 0.025%, the private label equivalent of Lumify in U.S. Lumify is an over-the-counter eyedrop that can be used to relieve redness of the eye due to minor eye irritations. The agreement also provides Dr. Reddy's exclusive rights to the product outside the U.S. Slayback Pharma is the first company to file an ANDA for the private label equivalent for Lumify with the USFDA under Paragraph IV certification. The ANDA is currently under USFDA review and covers Brimonidine Tartrate Ophthalmic Solution 0.025% in 2.5 ml and 7.5 ml fill volumes. "We are pleased to license this important OTC ophthalmic product for the U.S. market," says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's. "This product complements Dr. Reddy's growing OTC product portfolio in the eyecare category that includes the private label versions of Pataday Once Daily Relief and Pataday Twice Daily Relief."

13:14 EDT Microsoft posts blog detailing work with partner Plug Power - In a post to Microsoft's "Innovation Stories" blog dated July 28, author John Roach states in part: "Hydrogen fuel cells packed into a pair of 40-foot-long shipping containers here ramped up on an overcast day early this June as engineers gathered around laptops displaying data on the state, health and power output of the cells in this first-of-a-kind hydrogen generator... A round of applause and shouts of joy from engineers at Plug, who built the fuel cell system, pierced the white noise from fans atop the shipping containers and pipes venting steam. The moment was the latest milestone on Microsoft's quest to find a zero-carbon emissions replacement for the backup diesel-powered generators that support continuous operations in the event of power outages and other service disruptions... The PEM fuel cell test in Latham demonstrated the viability of this technology at three megawatts, the first time at the scale of a backup generator at a datacenter. Once green hydrogen is available and economically viable, this type of stationary backup power could be implemented across industries, from datacenters to commercial buildings and hospitals... The challenge to build a three-megawatt fuel cell system resonated with engineers at Latham-based Plug, a pioneer in the commercial development of fuel cell and green hydrogen technologies. Today, the company offers solutions throughout the green hydrogen ecosystem - from production and transportation to storage, handling and dispensing... The 125-kilowatt fuel cells - 18 of which are packed into each shipping container - are the largest the company has ever made, and the three-megawatt fuel cell system is Plug's biggest application. Because the system is larger than anything built before, so too are all the components, from compressors and heat exchangers to grid-scale inverters and the pipes for hydrogen delivery." Reference Link

13:04 EDT SEC adds Alibaba to Holding Foreign Companies Accountable Act list

13:02 EDT Baker Hughes reports U.S. rig count up 9 to 767 rigs - Baker Hughes reports that the U.S. rig count is up 9 from last week to 767 with oil rigs up 6 to 605, gas rigs up 2 to 157 and miscellaneous rigs up 1 to 5. The U.S. Rig Count is up 279 rigs from last year's count of 488 with oil rigs up 220, gas rigs up 54 and miscellaneous rigs up 5. The U.S. Offshore Rig Count is up 1 to 17, up 3 year-over-year. The Canada Rig Count is up 9 from last week to 204, with oil rigs up 13 to 137, gas rigs down 4 to 67. The Canada Rig Count is up 51 rigs from last year's count of 153, with oil rigs up 44, gas rigs up 8 and miscellaneous rigs down 1.

12:37 EDT Peoples Financial raises quarterly dividend to 40c from 39c - Peoples Financial's board declared a third quarter dividend of 40c per share, which represents a 5.3% increase over the dividend declared in Q3 of 2021. The dividend is payable September 15, to shareholders of record August 31.

12:00 EDT Avantor falls -13.2% - Avantor is down -13.2%, or -$4.27 to $28.06.

12:00 EDT Holley falls -35.9% - Holley is down -35.9%, or -$4.54 to $8.12.

12:00 EDT AMTD Digital rises 36.7% - AMTD Digital is up 36.7%, or $66.01 to $246.01.

11:56 EDT Stoke treatment of autosomal dominant optic atrophy granted orphan status - Stoke Therapeutics' treatment of autosomal dominant optic atrophy was granted orphan designation by the FDA, according to a post to the agency's website. Reference Link

11:41 EDT NeoPhotonics trading halted, news pending

11:21 EDT General Dynamics Electric Boat awarded $698M contract modification - General Dynamics Electric Boat, a business unit of General dynamics, announced it was awarded a modification of the previously awarded U.S. Navy contract for the repair, maintenance and modernization of the submarine USS Hartford. The contract modification has a value of $697.9M. Work will be performed at the company's shipyard in Groton, Connecticut, and is expected to be completed by October 2026. USS Hartford is a Los Angeles-class submarine built by General Dynamics Electric Boat and commissioned in 1994. "This engineered overhaul of the USS Hartford will enhance its warfighting capability and extend the ship's service life, returning a valuable asset to the U.S. Navy submarine fleet," said Kevin Graney, president of General Dynamics Electric Boat.

11:12 EDT AB Value-Radoff Group accepts settlement terms by Rocky Mountain Chocolate - AB Value Management and Bradley Radoff (together with their affiliates, who own approximately 17.6% of the outstanding shares of Rocky Mountain Chocolate Factory issued the following statement: "Earlier this week, our representative informed Rocky Mountain's legal counsel that we agree to all of the Company's latest publicly disclosed settlement terms. The framework we have agreed to provides for the addition of our nominee to the Board of Directors and other customary terms. By compromising with Rocky Mountain, we hope to facilitate improved corporate governance and enhanced value creation over the long-term. We intend to engage in good faith to expeditiously finalize a cooperation agreement that can benefit all of the Company's stockholders."

10:40 EDT VRAX Stock trading resumes

10:22 EDT Lottery.com down 48% to 42c per share after company raises 'going concern' doubt - In a regulatory filing, Lottery.com disclosed that on July, 28, the board of directors of the company determined that the company does not currently have sufficient financial resources to fund its operations or pay certain existing obligations, including its payroll and related obligations. "Additionally, the company's capital resources are not sufficient to fund its operations for a twelve-month period and, therefore, there is substantial doubt about the company's ability to continue as a going concern," the filing stated.

10:02 EDT Avaya appoints Masarek as President, CEO - Last night, Avaya Holdings announced that Alan Masarek has been appointed as its President and CEO and as a member of Avaya's Board of Directors, effective August 1, 2022. Masarek will succeed Jim Chirico, who will be removed from his positions as President and CEO of Avaya, effective August 1, 2022, and is resigning as a member of Avaya's Board. Chirico will remain employed with Avaya through August 16, 2022 and will work with Masarek to ensure a smooth transition for all stakeholders. Masarek most recently served as CEO of Vonage Holdings.

10:00 EDT Avantor falls -14.1% - Avantor is down -14.1%, or -$4.55 to $27.78.

10:00 EDT Graham rises 15.5% - Graham is up 15.5%, or $1.02 to $7.62.

10:00 EDT Getty Images rises 110.1% - Getty Images is up 110.1%, or $11.56 to $22.06.

09:50 EDT Nutriband Inc trading resumes

09:47 EDT Avantor falls -12.4% - Avantor is down -12.4%, or -$4.01 to $28.32.

09:47 EDT Fathom Digital rises 9.9% - Fathom Digital is up 9.9%, or 41c to $4.55.

09:47 EDT Getty Images rises 148.0% - Getty Images is up 148.0%, or $15.54 to $26.04.

09:40 EDT Nutriband Inc trading halted, volatility trading pause

09:40 EDT Genenta Science SpA(ADR) trading resumes

09:32 EDT Altius Renewable announces $40M financing of Hodson Energy - Altius Renewable Royalties announces that its jointly controlled subsidiary, Great Bay Renewables, has entered into a transaction with U.S. renewable energy developer, Hodson Energy, to gain future royalties related to Hodson's portfolio of solar plus battery storage development projects. Great Bay is jointly controlled by ARR and certain funds managed by affiliates of Apollo Global Management. New York-based Hodson is committing its entire portfolio of solar plus storage projects located primarily in the Mid-Atlantic region of the U.S. and any additional projects added in the future to this new royalty investment structure with Great Bay. Great Bay will receive a royalty on all projects developed and vended by Hodson until a minimum total return threshold is achieved. The targeted IRR threshold is consistent with the upper part of Great Bay's previously disclosed 8-12% base hurdle rate range before factoring in potential longer-term option value realizations. The $40M royalty investment into Hodson will be invested in tranches over approximately the next three years as Hodson achieves certain project advancement milestones, with an initial investment upon closing of $14M. Approximately US$9.8 million of the initial investment will be used to retire an existing development loan facility and acquire new projects, resulting in a 1.8 GWac total portfolio post-Great Bay investment. As individual pipeline projects are developed, Great Bay will receive a 3% gross revenue royalty on each project. This will continue until a target minimum total royalty portfolio valuation threshold is achieved. Once created, individual royalties will apply during the full life of the respective projects. In addition to royalties, Great Bay has the option to receive a portion of the proceeds from project sales. Any cash Great Bay elects to receive under this option would count toward the target return. Great Bay also has the option to invest an additional $20 million as royalty financing in the future.

09:27 EDT AbbVie says Q2 results 'exceeded our expectations' - Says "pleased with momentum" across therapeutic portfolio. Says broad portfolio "demonstrating strong revenue growth." Comments taken from Q2 earnings conference call.

09:24 EDT Centerra Gold completes gold arrangement agreement with Kyrgyzaltyn - Centerra Gold announced the closing of the previously announced global arrangement agreement with Kyrgyzaltyn JSC and the Government of the Kyrgyz Republic relating to the disposition of Centerra's ownership of the Kumtor mine and investment in the Kyrgyz Republic and the termination of Kyrgyzaltyn's involvement with the Company. As a result of the completion of the Transaction, Centerra has purchased and cancelled all of Kyrgyzaltyn's 77,401,766 Centerra common shares in exchange for, among other things, Centerra's 100% equity interest in its two Kyrgyz subsidiaries, and indirectly, the Kumtor mine, and aggregate cash payments of approximately $85M. As contemplated by the Arrangement Agreement, the parties have, among other things, provided full and final releases of all claims related to the Kumtor mine. In addition, Kyrgyzaltyn's two director nominees, Dushen Kasenov and Nurlan Kyshtobaev, have resigned from Centerra's Board of Directors, and the Restated Shareholders Agreement between, among others, Centerra and Kyrgyzaltyn has terminated. As a result of the purchase and cancellation of a total of 77,401,766 Centerra common shares previously held by Kyrgyzaltyn pursuant to the Transaction, the Company has 220,083,541 Centerra common shares outstanding as at the date hereof.

09:19 EDT Procter & Gamble sees FY23 EPS growth in line to up 4% vs. FY22

09:18 EDT P&G sees trade costs higher in FY23 by about $300M after tax vs. FY22

09:17 EDT Cosmos Holdings to change name to Cosmos Health - Cosmos Holdings announced that it is changing the name of the Company to Cosmos Health to better reflect the Company's evolution into a global healthcare group with a focus on improving people's lives. "The Cosmos Health brand marks a new chapter in the Company's evolution and better reflects our commitment towards a leading, highly scalable and innovative global healthcare group based on our R&D partnerships, fully licensed production facilities and fast deployment to distribution channels. This is in alignment with the Company's recent announcements about R&D partnerships and a proposed acquisition of a fully licensed Good Manufacturing Practices medical manufacturing facility with an outstanding scientific personnel, represents with the utmost accuracy the plan that is being implemented towards the goal of becoming a leading global healthcare group," stated Greg Siokas, CEO of Cosmos Health. "Our ecosystem enables cutting-edge technology and top-tier R&D departments to produce innovative and unique formulations for new pharmaceuticals and nutraceuticals, primarily focusing on major health disorders and prevalent diseases. Our organization's principles are the beacon to continue to build, progress and enhance this ecosystem under the Cosmos Health banner."

09:11 EDT Frequency Electronics announces $6.3M award for high precision oscillators - Frequency Electronics announces the selection of its high precision oscillators and frequency generation products for a critical military satellite system. The award is a follow-on option on a current contract and is valued at approximately $6.3 million dollars. The period of performance is approximately 24 months. No other details of the contract are being released at this time.

09:09 EDT Borqs Technologies' Holu Hou signs $2.5M sale agreement - Borqs Technologies announced that its solar energy subsidiary, Holu Hou Energy signed a $2.5M sale agreement and contract for construction of a renewable energy and energy storage system at the Mahana multi-family residential property located in Barbers Point. The Kalaeloa area has historically experienced high electricity rates and thus has been a target for introduction of renewable energy over the last several years. Under the agreement, HHE will construct what is a 2nd Phase to the Mahana property, bringing the total amount of solar there to approximately 640kW. In addition, the expansion at Mahana will incorporate 1.1 MWh / 284 kW of energy storage, which in addition to serving the needs of the residents, will also participate in the Hawaii Battery Bonus Program approved by the Hawaii Public Utility Commission in June 2021.

09:07 EDT Galecto expects cash to fund requirements into 2H24 - Cash, cash equivalents, and investments as of June 30, 2022 were approximately $85.9 million. The Company anticipates that its cash, cash equivalents and investments will be sufficient to fund operating expenses and capital requirements into the second half of 2024.

09:04 EDT TrueCar sees July total new vehicle industry sales 1,119,712, down 10% - TrueCar expects total new vehicle industry sales to reach 1,119,712 units in July 2022, down 10% from a year ago and down 2% from June 2022, when adjusted for the same number of selling days. This month's seasonally adjusted annualized rate for total light vehicle industry sales is an estimated 13 million, down 15% from July 2021. Excluding fleet sales, TrueCar expects U.S. retail deliveries of new cars and light trucks to be 975,597 units, down 14% from a year ago and down 1% from June 2022. "This month we're seeing the first response from the industry to address affordability concerns, by increasing incentives for the first time in nearly 20 months," said Zack Krelle, Industry Analyst at TrueCar. "Even before the latest bump in federal interest rates, consumers were facing rising challenges to vehicle affordability. As rates go up, consumers are faced with increased monthly payments, even as average transaction prices remain flat."

09:01 EDT Ecopetrol announces deepwater gas discovery in Colombia - Ecopetrol (EC) announces the discovery of a natural gas accumulation in the Uchuva-1 exploratory well in the Tayrona Block, drilled in Colombian deep waters, in which Petrobras (PBR) acts as operator with a 44.4% stake and Ecopetrol with a 55.6% stake. This gas discovery is aligned with Ecopetrol's 2040 energy transition strategy and increases the prospects for developing a new exploration and production frontier in the northern Colombian Caribbean. The contractor will continue the activities in the Tayrona Block with the objective of validating the dimensions of the new gas accumulation.

08:57 EDT Omeros announces FDA granted ODD to OMS908 - Omeros announced that OMS906 has received orphan drug designation, ODD, from the U.S. Food and Drug Administration, FDA, for the treatment of paroxysmal nocturnal hemoglobinuria, PNH. OMS906 targets mannan-binding lectin-associated serine protease-3, MASP-3, the key activator of the alternative pathway of the complement system. MASP-3 converts pro-complement factor D, pro-CFD, to mature CFD. "We are excited to begin clinical studies to demonstrate the efficacy of OMS906 in alternative pathway-related disorders," said Gregory Demopulos, M.D., chairman and chief executive officer of Omeros. "Based on our preclinical and Phase 1 trial data, we expect that OMS906 will perform well. With the potential advantages of MASP-3 inhibition and OMS906 - decreased infection risk, better dosing profile, and the ability to avoid 'breakthrough' disease seen with agents targeting acute phase reactants - we believe that OMS906 could become first-line therapy in alternative pathway disorders." Omeros recently completed a Phase 1 trial of OMS906 in healthy subjects and expects to begin enrollment this summer in a clinical trial assessing OMS906 in PNH patients who have had an unsatisfactory response to the C5 inhibitor ravulizumab. The company is also targeting efficacy data in populations of treatment-naive PNH and C3 glomerulopathy patients by early 2023. Based on the results of the completed Phase 1 trial, administration of OMS906 is expected to be once monthly to once quarterly intravenously or subcutaneously.

08:56 EDT UTStarcom launches SkyFlux UAR Disaggregated Router - UTStarcom announced its newest platform, the SkyFlux UAR Disaggregated Router. The platform applies the network disaggregation concept onto carrier-grade modular redundant router platforms optimized for telecommunications networks, resulting in an open, flexible, and future-proof solution that can meet the requirements of telecom applications such as 5G backhaul/midhaul, broadband aggregation, metro access and aggregation networks.

08:48 EDT Converge Technology completes acquisition of GfdB, IfmB, DEQSTER - Converge Technology Solutions announced the closing of its previously announced definitive agreement to acquire Germany-based organizations Gesellschaft fur digitale Bildung, Institut fur moderne Bildung and DEQSTER. Converge announced it had entered into the definitive agreement on June 15, 2022. Headquartered in Germany, GfdB, IfmB, and DEQSTER are all education market focused organizations enabling schools and universities to implement their digital future. GfdB and IfmB are full-service IT suppliers for education, offering everything from hardware and software to advanced training and comprehensive technical/consulting services. DEQSTER specializes in the development and production of equipment for digital learning and working, with a broad portfolio comprising of tablet cases, protective sleeves, digital pencils, and more.

08:39 EDT American Resources' Carnegie 1 set to double metallurgical carbon production - American Resources announced that it is in development of its second section that will operate as a continuous haulage bridge section, which upon completion, is expected to add $2.25 to $3.5 million per month of revenue at current market prices. The Company's Carnegie 1 team is currently setting up the ventilation required to start the added bridge section which is anticipated to start production in the next 60 to 90 days. The Carnegie 1 mine produces high vol metallurgical carbon that is not burned for energy use. Instead, specific characteristics allow it to be blended with iron to make new steel. This quality of product is in high demand in the current market environment given worldwide infrastructure growth coupled with persistent supply constraints as many producers in the U.S. are producing from old mines that are expensive to operate and coming to end-of-life. American Resources is focused on mine plans and operations that are built to be low cost with a mine life ranging from 20 to 40+ years while also making them safer and more productive operations.

08:38 EDT VivoPower announces pricing of $5.5M registered direct offering - VivoPower International announced that it has entered into a definitive agreement with a single U.S. institutional investor for the purchase and sale of 4,230,770 ordinary shares of the Company at an offering price of $1.30 per share, for gross proceeds of approximately $5.5 million before deducting fees and other estimated offering expenses, pursuant to a registered direct offering. The Company has also agreed to issue to the investor, in a concurrent private placement, unregistered warrants to purchase up to 4,230,770 of the Company's ordinary shares. The warrants will have an exercise price of $1.30 per ordinary share, will be exercisable on the six-month anniversary of the issuance date and will expire five years from initial exercise date. The closing of the offering is expected to occur on or about August 2, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to hire additional engineering talent, progress the scale up of assembly and production capabilities in key markets globally and for general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.

08:37 EDT MamaMancini's adds over 4,000 spots on retailer shelves - MamaMancini's Holdings announced that it has secured new customer authorizations, representing over 4000 new spots on the shelves of tier-1 nationwide retailers. The new spots are expected to increase MamaMancini's sales to its guidance of over $100M in annualized sales by fiscal year end. The new retailer commitments secured include a new product placement at BJ's Club Stores, Hannaford Food Stores rotation, The Fresh Market, Albertsons Safeway, Acme/Safeway Stores Division of Albertsons, Shop Rite Stores, Raley's, Key Foods Cooperative, Lowes Stores, and Food Town Cooperative. Products ordered range from six varieties of meals for one to go, beef meatballs in sauce for the deli, four pasta bowls, MamaMancini's branded club store Jumbo Beef Meatballs retail pack, MamaMancini's Branded Meatballs in a Cup, grilled chicken breasts, breaded chicken breasts, balsamic chicken breasts, meat loaf and tangy sauce, and meat loaf and bacon jam sauce. The new placements are largely expected to begin shipment from August through October 2022. When taken in tandem with several additional new placement wins expected in the coming months, these orders move the Company beyond with its expectation of a $100M annualized sales run rate by year-end.

08:35 EDT Altus Power announces inaugural sustainability report - Altus Power released its 2021 Sustainability Report. "Our team is proud to put our commitment to sustainability into writing and provide the first measurements of our company's Environmental, Social and Governance attributes in clear view for all of our stakeholders to see," commented Lars Norell, Altus' Co-Chief Executive Officer. "While we've only been a public company for 7 months, our team was resolute in issuing this initial report and is determined to update and improve these measurements in subsequent reports."

08:33 EDT Nielsen receives regulatory approval for proposed transaction - Nielsen Holdings announced it has received all necessary governmental regulatory approvals required to complete its previously announced proposed transaction with a consortium of private investment funds led by Evergreen Coast Capital, an affiliate of Elliott Investment Management, and Brookfield Business Partners, together with institutional partners. Nielsen also announced that Glass, Lewis & Co., a leading proxy advisory firm, recommended shareholders vote for the proposal to approve the proposed transaction. The Glass Lewis recommendation follows a July 25 report from Institutional Shareholder Services, another leading independent proxy advisory firm, also recommending that shareholders vote for the proposed transaction. Nielsen has two shareholder meetings scheduled for August 9: a "Court Meeting" and a "Special Meeting." The key business of these shareholder meetings is to vote on certain proposals for Nielsen to be acquired for $28.00 per share in cash by the Consortium. At the Court Meeting, shareholders will vote on whether to approve the proposed transaction by way of a scheme of arrangement.

08:31 EDT Integra Resources Corp trading halted, news pending

08:22 EDT Moderna enters contract with U.S. government for 66M COVID-19 booster doses - Moderna announced that the U.S. government has secured 66 million doses of a Moderna COVID-19 vaccine booster candidate, mRNA-1273.222, a bivalent booster candidate containing Spikevax plus the Omicron BA.4/5 strain mRNA. The contract includes an award of up to $1.74 billion for the manufacture and delivery of 66 million doses of mRNA-1273.222, as well as options to purchase up to an additional 234 million doses of COVID-19 vaccine booster candidates from Moderna.

08:20 EDT Trevena announces registered direct offering of common stock - Trevena announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for the purchase and sale of 1,800 shares of Series A convertible preferred stock and 200 shares of Series B convertible preferred stock and warrants exercisable to purchase up to an aggregate of 8,000,000 shares of common stock in a registered direct offering. Each share of preferred stock has a stated value of $1,000 per share and a conversion price of $0.25 per share. The shares of preferred stock issued in the offering are convertible into an aggregate of 8,000,000 shares of common stock. The warrants have an exercise price of $0.263 per share, will be exercisable beginning on the later of six months following the date of issuance and the effective date of a reverse stock split of the Company's common stock in an amount sufficient to permit the exercise in full of the warrants, subject to stockholder approval of the reverse stock split, and will expire five and one-half years following the date of issuance. The closing of the offering is expected to occur on or about July 29, 2022, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The Company expects to call a special meeting of stockholders for the approval of a proposal to effect a reverse stock split of the Company's common stock. The Series A Preferred has voting rights on the Proposal equal to the number of shares of common stock into which the Series A Preferred is convertible based on the minimum price under Nasdaq rules on the date of the securities purchase agreement. The Series B Preferred has voting rights on the Proposal equal to 25,000,000 votes per share of Series B Preferred, provided that any votes cast by the Series B Preferred with respect to the Proposal must be counted by the Company in the same proportion as the shares of common stock and Series A Preferred voted on the Proposal. The shares of preferred stock are convertible at the option of the holder at any time following the date of issuance. Total gross proceeds from the offering, before deducting the placement agent's fees and other estimated offering expenses, is $2 million. The Company intends to use the net proceeds from this offering for general corporate purposes, which may include working capital and general and administrative expenses.

08:16 EDT Westhaven Gold completes oversubscribed non-brokered private placement - Westhaven Gold announced that it has now closed the previously announced non-brokered private placement. The Company issued a total of 9,739,847 common shares that qualify as "flow-through shares" of the Company for the purposes of the Income Tax Act at a price of C$0.44 per Flow-Through Common Share for aggregate gross proceeds of $4,285,533. The gross proceeds from the Offering will be used to incur "Canadian exploration expenses" related to Westhaven's projects in British Columbia, Canada. The Company will renounce these expenses to the purchasers with an effective date of no later than December 31, 2022. The private placement remains subject to TSX Venture Exchange approval. The Company paid finders' fees of $39,001 to Red Cloud Securities Inc., $18,876 to National Bank Financial Inc., and $1,320 to Haywood Securities Inc. All securities issued in the Offering are subject to a hold period expiring on November 30th, 2022.

08:16 EDT KB Home announces opening of The Traditions at Marbella Ranch in Arizona - KB Home announced the grand opening of its model homes at The Traditions at Marbella Ranch, a new-home community in Glendale, Arizona. "The Traditions at Marbella Ranch is situated in a prime Northwest Phoenix location convenient to Interstate 10, U.S. Highway 60 and Loop 101, providing easy access to downtown Phoenix, the area's major employment centers, outdoor recreation and several entertainment venues," said Kevin McAndrews, President of KB Home's Phoenix division. "We are excited to open new model homes at our community and provide home shoppers with the opportunity to experience a new KB home that can be personalized to reflect their lifestyle and needs."

08:11 EDT Apollo provides EUR 500M investment into Air France affiliate - Apollo (APO) announced the close of an agreement for Apollo-managed funds and affiliated entities to make a EUR 500 million investment into an Air France operating affiliate owning a pool of spare engines dedicated to the airline's Engineering and Maintenance activities. Air France is a fully owned subsidiary of Air France-KLM (AFLYY). Apollo leveraged cross-platform expertise, including in aviation, asset-backed finance and multi-asset credit to execute the long-term investment. Proceeds from the transaction allow Air France-KLM and Air France to further redeem the French State perpetual bonds provided as State aid due to the COVID-19 outbreak.

08:10 EDT Arbor Realty raises quarterly dividend to 39c per share - The Company announced that its Board of Directors has declared a quarterly cash dividend of $0.39 per share of common stock for the quarter ended June 30, 2022. The dividend is payable on August 31, 2022 to common stockholders of record on August 15, 2022. The ex-dividend date is August 12, 2022.

08:05 EDT Grainger raises FY22 daily growth view to 14.5%-16.5% from 11%-14% - Raises FY22: Gross profit margin view to 37.2%-37.5% from 36.8%-37.3%; Operating cash flow view to $1.25B- $1.35B from $1.15B-$1.35B; CapEx to $300M-$325M from $275M-$325M.

07:59 EDT Lexagene Holdings announces filing of financial statements, revocation of MCTO - LexaGene Holdings announced that the Company has filed its Canadian audited financial statements for the year ended February 28, 2022 and the related management's discussion and analysis and certifications and the unaudited interim financial statements, management's discussion and analysis and related certifications for the three-months ended May 31, 2022. As a result, the management cease trade order issued by the British Columbia Securities Commission on June 30, 2022 has been revoked and is no longer in effect. The Company also announces that, pursuant to its Omnibus Incentive Plan, 1,085,000 stock options and 1,525,000 restricted share units were granted to employees and to an officer of the Company. The CEO, CFO and the board of directors were excluded from this grant. The stock options are exercisable at a price of C$0.20 and vest 10% on January 29, 2023 and 15% each of the 6 months thereafter. 935,000 stock options have an expiry date of July 29, 2027 and 150,000 stock options have an expiry date of July 29, 2032. On July 28, 2022, the last day that the Common Shares traded prior to the granting of the stock options, the closing price of the Common Shares on the TSX Venture Exchange was C$0.13 per share. The restricted share units were granted to employees and to an officer of the Company with a vesting schedule of 10% on December 29, 2022, and 15% on May 29, 2023, October 29, 2023, March 29, 2024, August 29, 2024, December 29, 2024 and February 28, 2025, respectively, and expire on February 28, 2025. The incentive stock options and restricted share unit awards were approved by the independent compensation committee of LexaGene's board of directors.

07:56 EDT Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials - Novo Nordisk announced headline results from the ONWARDS 3 and ONWARDS 4 phase 3a trials with once-weekly insulin icodec in adults with type 2 diabetes. ONWARDS 3, a phase 3a, double-blind 26-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec vs insulin degludec, achieved its primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 26 with insulin icodec compared with insulin degludec. From an overall baseline HbA1c of 8.5%, once-weekly insulin icodec achieved a superior reduction in estimated HbA1c of -1.57% compared with -1.36% for insulin degludec. In the trial, there was no statistically significant difference in estimated rates of severe or clinically significant hypoglycaemia with 0.31 events per patient-year exposed to once-weekly insulin icodec and 0.15 events per patient-year exposed to insulin degludec. In the trial, once-weekly insulin icodec appeared to have a safe and well-tolerated profile. ONWARDS 4, a phase 3a, 26-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec vs insulin glargine U100, both in combination with mealtime insulin, achieved its primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 26 with insulin icodec compared with insulin glargine. From an overall baseline HbA1c of 8.3% once-weekly insulin icodec achieved a reduction in estimated HbA1c of -1.16% compared with -1.18% for insulin glargine. In the trial, there was no statistically significant difference in estimated rates of severe or clinically significant hypoglycaemia with 5.64 events per patient-year exposed to once-weekly insulin icodec and 5.62 events per patient-year exposed to insulin glargine. In the trial, once-weekly insulin icodec appeared to have a safe and well-tolerated profile. "We are very pleased to see that the results from ONWARDS 3 and 4 reinforce the potential of once-weekly insulin icodec to simplify basal insulin therapy for people with type 2 diabetes as an ideal starter insulin and as an attractive option in combination with mealtime insulin", said Martin Holst Lange, executive vice president for Development at Novo Nordisk. "We are now looking forward to sharing the results from ONWARDS 5 - the last remaining trial in the ONWARDS programme in the second half of this year."

07:44 EDT AbbVie reports Q2 U.S. Humira net revenues were $4.664B, up 9.6% - In Q2: Global net revenues from the immunology portfolio were $7.207 billion, an increase of 17.8 percent on a reported basis, or 19.2 percent on an operational basis. Global Humira net revenues of $5.363 billion increased 5.8 percent on a reported basis, or 6.8 percent on an operational basis. U.S. Humira net revenues were $4.664 billion, an increase of 9.6 percent. Internationally, Humira net revenues were $699 million, a decrease of 13.8 percent on a reported basis, or 7.3 percent on an operational basis, due to biosimilar competition. Global Skyrizi net revenues were $1.252 billion, an increase of 85.9 percent on a reported basis, or 88.3 percent on an operational basis. Global Rinvoq net revenues were $592 million, an increase of 56.3 percent on a reported basis, or 60.7 percent on an operational basis. Combined global Skyrizi and Rinvoq net revenues were $1.844 billion.

07:36 EDT Cboe raises FY22 organic net revenue growth view to 9%-11% from 5%-7% - Cboe provided guidance for the FY22: Sees organic net revenue growth 9%-11%, up from previous guidance of 5%-7%; reaffirmed revenue from acquisitions held less than a year is expected to contribute total net revenue growth in a range of 2%-3%; organic net revenue from Data and Access Solutions is now expected to increase by approximately 10%-13%, from a base of $419M in 2021, up from previous guidance of 8%-11%; adjusted operating expenses in 2022 are now expected to be $659M-$667M, from a base of $531M in 2021, up from previous guidance of $617M-$625M. The updated 2022 guidance considers incremental investment spend in technology and headcount to support Cboe's numerous growth initiatives, deals closed during 2021 but not fully reflected in the 2021 cost base, recent acquisitions of NEO and ErisX and increases in core expenses. The guidance excludes the expected amortization of acquired intangible assets of $125M; the company plans to reflect the exclusion of this amount in its non-GAAP reconciliation. Reaffirmed depreciation and amortization expense for 2022, which is included in adjusted operating expenses above, is expected to be in the range of $40M-$44M, excluding the expected amortization of acquired intangible assets. Reaffirmed the effective tax rate on adjusted EPS is expected to be in the range of 27.5%-29.5%. Significant changes in trading volume, expenses, tax laws or rates and other items could materially impact this expectation. Reaffirmed capital expenditures are expected to be $47M-$52M.

07:35 EDT CNH Industrial approves additional $300M share buy-back program - The Board of Directors approved a $300 million share buyback program to be launched at the completion of the existing $100 million program.

07:21 EDT Enanta announces data from Phase 1 study of EDP-235 - Enanta Pharmaceuticals announced positive topline data from a Phase 1 study assessing the safety, tolerability, and pharmacokinetics, PK, of orally administered single ascending doses, SAD, and multiple ascending doses, MAD, of EDP-235 in healthy adult subjects. EDP-235, a coronavirus 3CL protease inhibitor, which received Fast Track designation from the U.S. Food and Drug Administration, is specifically designed to be a once-daily, oral antiviral treatment for COVID-19. Data from the Phase 1 study demonstrated favorable safety, tolerability, and PK with strong exposure multiples over the EC90, thereby supporting the advancement of EDP-235 into a Phase 2 study using once-daily dosing, without ritonavir. "We are very pleased with the encouraging results from our Phase 1 study of EDP-235 showing that it was generally safe and well-tolerated up to a once-daily dose of 400mg, which provided plasma drug levels that were 6-fold and 12-fold over the plasma protein adjusted EC90 for the Alpha variant and the Delta variant, respectively. Moreover, EDP-235 is projected to have four times higher drug levels in lung tissue compared to plasma, which would drive exposure multiples to 24-fold and 48-fold for the respective variants," stated Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. This first-in-human, randomized, double-blind, placebo-controlled Phase 1 study enrolled healthy volunteers to evaluate the safety, tolerability, and PK of oral EDP-235 in SAD and MAD for seven days, and the effect of food. A total of 72 subjects received at least one dose of EDP-235 or placebo. Overall, EDP-235 was generally safe and well-tolerated in healthy subjects up to 400mg for up to seven days. The majority of adverse events were mild, with headache and gastrointestinal related symptoms being the most frequently reported AEs during the MAD phase. There were three study discontinuations: one moderate headache in the 400mg fasted cohort, one severe headache in the 800mg fed cohort and one grade 3 ALT/grade 2 AST elevation in the 800mg fed cohort. EDP-235 exposure increased approximately proportionally with increasing single and multiple doses, with a consistent half-life ranging from 13 to 22 hours, resulting in a PK profile suitable for once-daily dosing. Exposure was enhanced with food administration of a standard meal. EDP-235 once-daily taken with food, resulted in mean trough plasma levels at steady state that were higher than the plasma protein adjusted EC90 of EDP-235 in Vero. Based on these positive data, Enanta is moving forward with the clinical development of EDP-235, targeting a fourth quarter initiation of a Phase 2 study exploring doses of 200mg and 400mg once-daily, pending review with the FDA.

07:18 EDT The Digital IF Interoperability Consortium announces seven new members - The Digital IF Interoperability Consortium announced the addition of seven more members, from across industry sectors, including: CesiumAstro builds high-throughput, plug-and-play active phased array communications payloads for airborne and in-orbit platforms. Communications & Power Industries is a global manufacturer of electronic components and subsystems focused primarily on communications and defense markets. Keysight Technologies works with innovators to push the boundaries of engineering to design, emulate, test, and deliver breakthrough electronics.Ipsolon Research, Inc. was founded in August 2008 with an initial long-term contract to develop and improve the analog and digital signal processing system for an airborne obstruction penetrating LIDAR system. Rohde & Schwarz GmbH & Co., KG develops, produces, and markets a wide range of electronic capital goods for industry, infrastructure operators and government customers. Quasar Satellite Technologies, Pty Ltd. an Australian company focused on providing a world-leading ground station service for satellite operators and users. Kepler Communications provides real-time, continuous connectivity for space, abolishing barriers to make space-generated data universally accessible.

07:14 EDT Kaixin Auto holds launch ceremony for TECROLL brand - Kaixin Auto announces that it held the launch ceremony of the "TECROLL" brand in Beijing on July 28, 2022, which is the first model of new energy commercial vehicles released by Kaixin. A delivery ceremony was held at the launch. The model of electric logistics trucks is custom designed and made for Beijing Bujia Technology. The truck is made of aluminum with a total mass of 4.5 tons. It can be used in various scenarios including passenger car hauling and emergency rescue. Its core electrical parts far exceed the configurations of similar light trucks, with fast acceleration, strong climbing and low energy consumption.

07:12 EDT Xos secures purchase order from AUSEV - Xos announced it has secured a purchase order from AUSEV for one stripped chassis and has started conversations on working towards a manufacturing and distribution partnership in Australia. Upon receiving the stripped chassis, AUSEV will collaborate with Xos engineers on design and manufacturing issues specific to the Australian right-hand drive market.

07:09 EDT Charter sees FY22 cable CapEx $7.1B-$7.3B - Charter currently expects full year 2022 cable capital expenditures, excluding capital expenditures associated with its rural construction initiative, to be between $7.1B-$7.3B.

07:06 EDT Graham awarded $40.3M in orders in Q1 - Graham announced that it was awarded $40.3M in orders during its Q1. Within the $40.3M of total orders, there were several orders and trends noteworthy of mention: $10.0M for commercial aftermarket; $7.3M of combined pump/turbo pump orders to multiple customers in the space industry; $7.0M for vacuum distillation systems for a refinery in India; $5.6M of combined orders for critical U.S. Navy submarine and carrier programs. Daniel J. Thoren, President and CEO, commented, "We are truly excited about the breadth and diversity we are seeing in our backlog and order pipeline. We are engineering experts in complex fluid, power, heat transfer and vacuum systems and this expertise is being recognized in more growth-oriented markets of defense, space and alternative energy, which augments our global energy and process businesses."

07:04 EDT Allegiance Bancshares anticipates closing CBTX merger in Q3 - On November 8, 2021, Allegiance and CBTX jointly announced that they entered into a definitive merger agreement pursuant to which the companies will combine in an all-stock merger of equals. Under the terms of the definitive merger agreement, Allegiance shareholders will receive 1.4184 shares of CBTX, Inc. common stock for each share of Allegiance common stock they own. Following the completion of the merger, we estimate that former Allegiance shareholders will own approximately 54% and former CBTX shareholders will own approximately 46% of the combined company. The companies have received the requisite approvals from the Federal Deposit Insurance Corporation, Texas Department of Banking and both companies' shareholders and, subject to receipt of the approval of the Board of Governors of the Federal Reserve System and the satisfaction or in some cases waiver of the closing conditions, the parties anticipate closing in the third quarter of the year.

07:01 EDT Church & Dwight sees Q3 sales up 2%-4% - Matthew Farrell, CEO, commented, "In Q3, we expect reported sales growth of approximately 2%-4%, organic sales growth of approximately 1-3%, and gross margin contraction. Q3 organic sales expectations reflect a slowdown in discretionary brands such as Waterpik and Flawless and a difficult comparison for vitamins due to the prior year COVID spike from the Delta variant. We expect EPS of 65c per share, a 19% decrease from last year's adjusted Q3 EPS. This decline is influenced by inflation, higher expected SG&A and promotional support. In Q4, we expect higher organic growth and significant EPS growth due to accelerated trade down to our value portfolio, recovery of fill rates in personal care and promotional support closer to pre COVID levels. Prior year Q4 was also burdened by onetime charges and investments."

07:00 EDT Denison Mines confirms proposal for UEX Corporation - Denison Mines (DNN) has noted the disclosure made by Uranium Energy (UEC) in its news release dated July 28, 2022. Denison hereby confirms that it has made a confidential proposal to UEX Corporation to acquire all of the issued and outstanding shares of UEX. UEX has reported that its Board of Directors, in consultation with its legal and financial advisors, has determined that the Acquisition Proposal constitutes a "Superior Proposal" as defined in the Arrangement Agreement between UEC and UEX dated June 13, 2022. David Cates, President & CEO of Denison, commented: "We believe that an acquisition by Denison of UEX, and its assets in northern Saskatchewan, has the potential to benefit Denison shareholders - bolstering Denison's position as a leading uranium development and exploration Company with an unwavering focus on the advancement of high-grade uranium deposits in the Athabasca Basin region. Importantly, an acquisition of UEX would allow Denison to consolidate 100% ownership in our flagship Wheeler River Project at an ideal time ahead of the anticipated final technical de-risking steps associated with the Feasibility Study in progress for the planned Phoenix In-Situ Recovery operation."

06:44 EDT ImmunoGen reaffirms FY22 revenue view $75M-$85M, consensus $84.73M - Sees FY22 operating expenses $285M-$295M, and cash and cash equivalents at December 31 $245M-$255M. The company added, "Given the range in timing for potential approval, revenue guidance does not reflect potential product sales from mirvetuximab. ImmunoGen expects that its current cash, combined with anticipated product and collaboration revenues, will fund operations into 2024."

06:35 EDT Exxon Mobil reports Q2 free cash flow $16.9B - Net-debt-to-capital ratio improved to 13% reflecting a period-end cash balance of $18.9B. The debt-to-capital ratio was 20%, at the low-end of the company's target range.

06:25 EDT BlueCity's shareholders approve merger agreement - BlueCity Holdings announced that at an extraordinary general meeting of shareholders held today, the Company's shareholders voted in favor of, among other things, the proposal to authorize and approve the previously announced Agreement and Plan of Merger, dated as of April 30, among the Company, Multelements and Diversefuture, a wholly-owned subsidiary of Parent, pursuant to which the Merger Sub will be merged with and into the Company, with the Company being the surviving company and becoming a wholly-owned subsidiary of Parent, the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands and the consummation of the transactions contemplated thereby, including the Merger. The Merger Agreement, the Plan of Merger and the transactions contemplated thereby, including the Merger, were approved by approximately 95.7% of the total votes cast at the extraordinary general meeting, and were therefore duly authorized and approved by way of special resolutions as required by, and in compliance with, the Companies Act of the Cayman Islands. Completion of the Merger is subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement.

06:22 EDT Chevron reports Q2 U.S. downstream earnings $2.44B - U.S. downstream operations reported earnings of $2.44B in second quarter 2022, compared with earnings of $776M a year earlier. The increase was mainly due to higher margins on refined product sales, partially offset by lower earnings from the 50%-owned Chevron Phillips Chemical Company and higher operating expenses. Refinery crude oil input in second quarter 2022 decreased 8% to 881,000 barrels per day from the year-ago period, primarily due to planned turnarounds. Refined product sales of 1.21M barrels per day were up 4% from the year-ago period, mainly due to higher jet fuel demand as travel restrictions associated with the pandemic continue to ease.

06:18 EDT Chevron reports Q2 cash flow from operations $13.8B, free cash flow $10.6B

06:12 EDT U.S. Silica sees business segments 'well positioned for growth' in Q3 - "Looking forward to the third quarter and second half of 2022, the Company's two business segments remain well positioned for growth in their respective markets. The Company has a strong portfolio of industrial and specialty products that serve numerous essential, high growth and attractive end markets, supported by a robust pipeline of new products under development, as well as growth in its underlying base business and pricing increases and surcharges to continue to fight inflationary impacts.," the company said. The oil and gas industry is progressing through what is anticipated to be a multi-year growth cycle. Strength in both WTI crude oil and natural gas prices are promising for an active well completions environment throughout the second half of 2022 and into 2023. The Company remains focused on generating free cash flow and de-levering the balance sheet and intends on being operating cash flow positive in 2022, keeping an estimated $40-$60 million of capital expenditures within operating cash flow.

06:05 EDT NatWest Group sees FY22 net income around GBP 12.5B - The company said: "In 2022, we expect income excluding notable items to be around GBP 12.5 billion in the Go-forward group. We expect NIM to be greater than 2.70% for full year 2022 in the Go-forward group. We are investing around GBP 3 billion over 2021 to 2023 and, with continuing simplification, we plan to reduce Go-forward group operating expenses, excluding litigation and conduct costs, by around 3% in 2022 and to keep broadly stable in 2023, with positive jaws. We expect our 2022 and 2023 impairment charge to be lower than our through the cycle loss rate of 20-30 basis points, with 2022 below 10 basis points in the Go-forward group. In 2023, we expect to achieve a return on tangible equity in the range of 14-16% for the Group. We aim to end 2022 with a CET1 ratio of around 14% and target a ratio of 13-14% by 2023."

05:53 EDT ArcelorMittal announces new buyback program of 60,431,380 shares - ArcelorMittal announces a new share buyback program of 60,431,380 shares in the amount of approximately $1.4B under the authorization given by the annual general meeting of shareholders of May 4, bringing the total 2022 buybacks announced so far to approximately $3.4B. The program is expected to be completed by the end of May 2023, subject to market conditions.

05:39 EDT Intel winding down Optane memory business, says CEO Gelsinger - Intel CEO Pat Gelsinger, on the company's earnings conference call, said that in Q2, the company initiated the winding down of its Optane memory business. Intel's earnings report also noted that the company is taking a $559M "Optane inventory impairment" charge this quarter.